Replies to post #77996 on Anavex Life Sciences Corp (AVXL)

[blu_1]

This is not true. Missling said at Lartenburg, as well as the AAIC poster summary, that dosings are still 10-50mg through at least 31 weeks. clinicaltrials.gov said last month only 25% of subjects are on 50mg.

DZP stymies 273 I am convinced. Just look at the 7 only on 273 vs 273+dzp scores. DZP competitively competes with 273 for sigma sites and it has MUCH greater affinity for those sites than 273. DZP counters 273's agonism of the M1 receptor b/c it is a M1 antagonist. A paper even wrote that M1 antagonists cancel out drugs that agonize M1. Look at DZP's affect on TauRx's drug permformance, which targets M1. It cancels out TauRx's drug.

[McMagyar]

This is the post I referred to that inferred dosing had been changed to get better results. I don't think they changed dosing to 30mg and 50mg. I think some of the 27 patients are still at 10 mg . Can anyone find a different statement? Than MTD is not for EVERY patient but as a group, and each patient is NOT given their MTD which theoretically would UP the results.
It seems as if the varied dosages continued even at the lower levels NOT because of patients MTD but because that was a test point in the adaptive trial.
That is what the poster from 6 months mostly said, please find where Anavex has countered that statement.
Anyone?